|Department of Health|
|MEDICINES CONTROL AGENCY|
|Market Towers 1 Nine Elms Lane London SW8 5NQ|
|Telephone 0171-273 0600|
|Facsimile 0171- 273 0737||our ref: OG 98/18, 23 etc.|
|16 June 1998|
Dear Mr Medawar,
REQUESTS FOR INFORMATION RELATING TO THE COMMITTEE ON SAFETY OF MEDICINES
I am writing further to my letter of 30 April, your reply of 3 May and Professor Rawlins' response to you of 8 May concerning your various requests for information relating to the Committee on Safety of Medicines. I have summarised these as attached.
Professor Rawlins' reply said that members of CSM had decided not to provide you with the answers to your questions and invited you to raise this with the MCA if you wished to take this further. You said in a telephone conversation with Peter Dunlevy that you wished us so to do. We are considering these requests and I will write to you again as soon as I can.
As Dr Jones is now away until the end of this month, I will reply to your most recent letter of 3 June as soon as I can. We will also let you know as soon as possible the outcome of the review you requested of our decision of 6 February not to disclose information. I regret any inconvenience this may be causing. We will include our replies to the additional requests for information you made in your letter of 11 February.
I have also received your request of 4 June for Agency SOPs which we have linked with your previous request of 19 May, and also a copy of your further letter of 10 June to Professor Rawlins which you also ask to be dealt with under the Code of Practice and your letter of today's date about Dr Munro's review, to all of which I shall reply as soon as I can.
|Head of Executive Support|
|COMMITTEE ON SAFETY OF MEDICINES|
|Charles Medawar: Requests for information|
|The MCA is currently considering the following requests for information:|
Letter of 12 March to Prof. Rawlins
Letter of 10 March to Mr Alder
Letter of 20 March to Mr Whitbread
Mr Medawar has also asked in a letter of 14 May to Professor Rawlins for:
and a number of further questions in a letter of 10 June relating to the previous correspondence between him and Professor Rawlins on SSRIs.
|MCA Executive Support|
CLICK HERE TO READ ON